Evidence map›Paper›PMID 28938648›Full record

ArticleOncotarget2017

A novel lncRNA, LL22NC03-N64E9.1, represses KLF2 transcription through binding with EZH2 in colorectal cancer.

Yifan Lian, Changsheng Yan, Jie Ding, Rui Xia, Zhonghua Ma, Bingqing Hui, Hao Ji, Jing Zhou, Keming Wang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yifan Lian *The Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Changsheng Yan *Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, Jiangsu, People's Republic of China.
Jie Ding *Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Rui XiaDepartment of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, 210000 Jiangsu, People's Republic of China.
Zhonghua MaThe Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Bingqing HuiThe Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Hao JiThe Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Jing ZhouThe Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Keming WangThe Second Clinical Medical College of Nanjing Medical University, Nanjing 210000, Jiangsu, People's Republic of China.
Second Affiliated Hospital of Nanjing Medical University · CNJiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNA) have been implicated in variety human cancer but their mechanisms of function are mainly undocumented. In the present study, we investigated lncRNAs alteration that contributed to colorectal cancer (CRC) by utilizing TCGA RNA sequencing data and other publicly available lncRNAs expression profiling data. Here, We screened out the CRC-associated lncRNA LL22NC03-N64E9.1, a key regulator of CRC development and progression. We also revealed that knockdown of LL22NC03-N64E9.1 inhibited cell proliferation, colony formation, tumorigenicity and apoptosis promotion, both

Indexed as

colorectal cancerKLF2LL22NC03-N64E9.1lncRNAproliferation

Identifiers

PMID28938648
PMCPMC5601744
OpenAlexW2740744883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.